Travere’s Sparsentan Nears European Market Breakthrough
Company Announcements

Travere’s Sparsentan Nears European Market Breakthrough

Travere Therapeutics (TVTX) has released an update.

Sparsentan, a treatment for adults with primary IgA nephropathy (IgAN), is poised for a breakthrough in the European market, as the EMA’s CHMP has recommended its approval. Developed by Travere Therapeutics, Inc. and CSL Vifor, this potential new therapy, already under accelerated approval in the U.S., could soon be available across the EU and additional European countries following the European Commission’s final decision. Its unique position as a non-immunosuppressive, dual-action medication targets a significant need for those at risk of rapid disease progression, marking a potentially significant advancement in IgAN treatment.

For further insights into TVTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyTravere Therapeutics 7.81M share Spot Secondary priced at $16.00
TheFlyTravere Therapeutics announces common stock offering, no amount given
TheFlyTravere Therapeutics price target raised to $27 from $23 at Scotiabank
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App